{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:55:12Z","timestamp":1792716912693,"version":"4.5.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the risk of local recurrence in patients with multiple actinic keratoses (AKs), to analyze the influence of host-, lesion-, and treatment-related factors, and to develop and validate a Cox regression model for predicting recurrence risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study enrolled 148 patients with multiple AKs during January 2019-February 2022. Baseline characteristics, treatment modalities, and follow-up outcomes were collected. The Kaplan-Meier method was used to estimate cumulative recurrence rates. Cox regression analyses were performed to identify independent risk factors. The interaction effect between lesion count and treatment response was further assessed. A multivariate Cox predictive model was constructed, and its performance was validated using the 24-month calibration curve, Harrell\u2019s C-index, and Brier score. A nomogram was developed for individualized risk prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cumulative recurrence rates at 12, 24, and 36 months were 22.3%, 35.6%, and 44.7%, respectively. Multivariate analysis identified higher lesion count (11-20: HR = 2.39; &amp;gt; 20: HR = 2.96) and incomplete treatment response (HR = 2.43) as independent risk factors. Immunosuppression and regular sunscreen use were not significant. Although visual analysis suggested elevated risk with more lesions and incomplete response, their interaction term was not statistically significant. The model demonstrated moderate discrimination (C-index = 0.630) and good calibration (Brier score = 0.176). The nomogram enabled individualized risk estimation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lesion burden and incomplete treatment response significantly predict recurrence in multiple AKs patients. The developed Cox model and nomogram offer a clinically useful tool for identifying high-risk individuals and optimizing management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1770341","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:31:49Z","timestamp":1770787909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics and local recurrence risk in patients with multiple actinic keratoses: a retrospective clinical data analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhaogui","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Tenth Affiliated Hospital of Southern Medical University (Dongguan City People's Hospital)","place":["Dongguan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"He","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1518633","article-title":"From actinic keratosis to cutaneous squamous cell carcinoma: the key pathogenesis and treatments","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02490-5","article-title":"Treatment of actinic keratosis: a systematic review","volume":"315","author":"Worley","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061133","article-title":"Topical immunotherapy for actinic keratosis and field cancerization","volume":"16","author":"Bernal Masferrer","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.85270","article-title":"Single-cell sequencing highlights heterogeneity and Malignant progression in actinic keratosis and cutaneous squamous cell carcinoma","volume":"12","author":"Zou","year":"2023","journal-title":"Elife"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054989","article-title":"Pharmacological agents used in the prevention and treatment of actinic keratosis: A review","volume":"24","author":"Arcuri","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00668-9","article-title":"Intensity of local skin reactions during 5-fluorouracil treatment related to the number of actinic keratosis lesions: A post hoc, exploratory analysis","volume":"12","author":"Stockfleth","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14267","article-title":"A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index","volume":"31","author":"Dirschka","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19897","article-title":"European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Europ\u00e9enne des M\u00e9decins Sp\u00e9cialistes)","volume":"38","author":"Kandolf","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.017","article-title":"Long-term recurrence rates of actinic keratosis: A systematic review and pooled analysis of randomized controlled trials","volume":"86","author":"Steeb","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jdv.14092","article-title":"The importance of treating the field in actinic keratosis","author":"Stockfleth","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjd.17637","article-title":"From actinic keratosis to squamous cell carcinoma \u2013 answers to some open questions","volume":"180","author":"Welzel","year":"2019","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14730","article-title":"Targeted deep sequencing reveals genomic alterations of actinic keratosis\/cutaneous squamous cell carcinoma in situ and cutaneous squamous cell carcinoma","volume":"32","author":"Kim","year":"2023","journal-title":"Exp Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17061050","article-title":"Daylight photodynamic therapy for actinic keratosis and field cancerization: A narrative review","volume":"17","author":"Sotiriou","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15090421","article-title":"The state of the art in the treatment of actinic keratosis and field cancerization: A narrative review","volume":"15","author":"Paradisi","year":"2025","journal-title":"J Pers Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20452","article-title":"Long-term follow-up of a randomized, double-blind, phase III, multi-centre study to evaluate the safety and efficacy of field-directed photodynamic therapy (PDT) of mild to moderate actinic keratosis using BF-200 ALA versus placebo and the BF-RhodoLED(R) lamp","volume":"39","author":"Reinhold","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B16","article-title":"A retrospective review of histopathologic features associated with increased risk of recurrence of non-melanoma skin cancer after mohs micrographic surgery","volume":"15","author":"Agnetta","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-022-02432-0","article-title":"Clinicopathological profile, management and clinical outcomes in recurrent cases of ocular surface squamous neoplasia at a tertiary care centre","volume":"43","author":"Kumar","year":"2023","journal-title":"Int Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000548336","article-title":"Management of all patients with multiple actinic keratoses requires lifelong follow-up and repeated treatment cycles: A 12-year prospective observational study of a cohort of 81 patients","author":"Calzavara-Pinton","year":"2025","journal-title":"Dermatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70217","article-title":"Tirbanibulin 1% real-world use in 679 actinic keratoses patients during warm season (SUMM-AK study)","author":"Carugno","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2024.104056","article-title":"Assessing field cancerization and actinic keratosis using ultraviolet-induced fluorescence dermatoscopy after the application of 5-aminolevulinic acid - An observational study","volume":"46","author":"Korecka","year":"2024","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.jid.2020.12.024","article-title":"The genomic landscape of actinic keratosis","volume":"141","author":"Thomson","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.19559","article-title":"Actinic keratosis: Current challenges and unanswered questions","author":"Malvehy","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13447","article-title":"A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies","volume":"62","author":"Sinclair","year":"2021","journal-title":"Australas J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e70058","DOI":"10.1111\/phpp.70058","article-title":"Can urea 10% Promote photosensitizer uptake before MAL-PDT for the treatment of facial actinic keratoses? Results of a randomized clinical trial","volume":"41","author":"Artelli","year":"2025","journal-title":"Photodermatol Photoimmunol Photomed"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1770341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:22:16Z","timestamp":1771928536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1770341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1770341"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1770341","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1770341"}}